362. Paul Coletta, Co-Founder & CEO of Vero Bioscience

Today, I'm joined by Paul Coletta, co-founder & CEO of Vero Bioscience.

A predictive health company, Vero uses proteomic blood tests and proprietary AI to measure and improve organ-level aging.

In this episode, we discuss building a closed-loop health system powered by proteomics.

We also cover:

• Why organ-level data beats whole-body scores
• How proteomics differs from other biological age measures
• Reproducibility, clinical validation, and roadmap to launch

Subscribe to the podcast → insider.fitt.co/podcast

Subscribe to our newsletter → insider.fitt.co/subscribe

Follow us on LinkedIn → linkedin.com/company/fittinsider

Get on the waitlist: verobioscience.com

X (Twitter): https://x.com/Vero_Bioscience

Follow Paul: https://www.linkedin.com/in/paulcoletta

Follow Vero: https://www.linkedin.com/company/vero-bioscience-inc

Eudaimonia (Health Innovation Lab) in November: https://eudemonia.net/hil/

YouTube: https://www.youtube.com/@VeroBioscience

The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities.

Fitt Talent: https://talent.fitt.co/

Consulting: https://consulting.fitt.co/

Investments: https://capital.fitt.co/

Chapters:

(00:00) Introduction

(01:30) Paul's background

(02:45) 11K protein measurement

(04:00) Stanford technology

(05:00) Scientific validation

(06:00) Biological age vs. organ age

(07:30) Actionability and reproducibility

(10:00) Clinical validation approach

(12:15) Closed-loop compass system

(14:00) Organ-specific interventions

(15:30) Healthspan vs. immortality

(19:15) Clinical partnerships strategy

(22:00) Competitive differentiation

(25:00) Direct-to-consumer roadmap

(27:30) Regulatory and cost challenges

(28:30) Educating the market

(30:00) Balancing rigor and marketing

(34:00) Patient-led future

(36:45) Conclusion